Kiran Mazumdar-Shaw, Government Chairperson, Biocon Restricted
| Picture Credit score:
JAGADEESH N.V
Pharma main Biocon Restricted has reported a 56.8 per cent year-on-year (y-o-y) decline in consolidated web profit to ₹198.6 crore for Q4FY26, impacted by an distinctive merchandise outgo of ₹80.4 crore through the fourth quarter. Nonetheless, the corporate noticed progress in its core companies, with traction throughout the biosimilars and generics segments.
Income from operations for the quarter stood at ₹4,517 crore, up 13 per cent year-on-year, together with licensing revenue obtained through the interval.
Phase efficiency
The biosimilars business grew 16 per cent year-on-year to ₹2,756 crore through the quarter. The generics section, nevertheless, declined 17 per cent to ₹847 crore, whereas the CDMO business grew 3 per cent year-on-year to ₹1,037 crore.
“The mixed business has a stronger stability sheet, improved leverage metrics and a extra international business footprint. We are actually centered on profitability enhancement and long-term worth creation,” mentioned Kiran Mazumdar-Shaw, Government Chairperson, Biocon Restricted.
The corporate made a web R&D funding of ₹277 crore through the quarter.
In the course of the 12 months, the corporate built-in its biologics arm inside the Biocon group. Introduced in December 2025, the combination goals to create a unified international biopharmaceutical chief by combining the strengths of Biocon’s generics business with Biocon Biologics’ specialised biosimilars portfolio. The transfer was undertaken to keep away from the holding firm low cost related to Biocon Biologics and to unlock worth. The acquisition was supported by a virtually ₹4,500 crore certified institutional placement (QIP).
“Development was led by sturdy efficiency in superior markets and key tender wins throughout rising markets. With the combination now full, we shift gears in FY27 from the ‘Protect’ part of our technique to ‘Consolidate’, as we arrange the business for sustainable progress,” mentioned Shreehas Tambe, CEO and Managing Director, Biocon Restricted.
Revealed on Could 8, 2026
Source link
#Biocon #profit #drops #biosimilars #business #shines
